Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Non-Current Assets (2023 - 2025)

Contineum Therapeutics has reported Other Non-Current Assets over the past 3 years, most recently at $266000.0 for Q3 2025.

  • Quarterly results put Other Non-Current Assets at $266000.0 for Q3 2025, up 8766.67% from a year ago — trailing twelve months through Sep 2025 was $266000.0 (up 8766.67% YoY), and the annual figure for FY2024 was $3000.0, down 99.77%.
  • Other Non-Current Assets for Q3 2025 was $266000.0 at Contineum Therapeutics, up from $186000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CTNM hit a ceiling of $2.6 million in Q1 2024 and a floor of $3000.0 in Q2 2024.
  • Median Other Non-Current Assets over the past 3 years was $95000.0 (2025), compared with a mean of $546375.0.
  • Peak annual rise in Other Non-Current Assets hit 8766.67% in 2025, while the deepest fall reached 99.85% in 2025.
  • Contineum Therapeutics' Other Non-Current Assets stood at $1.3 million in 2023, then tumbled by 99.77% to $3000.0 in 2024, then skyrocketed by 8766.67% to $266000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $266000.0 (Q3 2025), $186000.0 (Q2 2025), and $4000.0 (Q1 2025) per Business Quant data.